Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05459909
Other study ID # SYN-DIET-OB-RCT
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 1, 2020
Est. completion date July 31, 2024

Study information

Verified date July 2022
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Synbiotic is a nutritional supplement that contains both prebiotic and probiotic. Probiotics are beneficial microorganisms, while prebiotics are foods that help the growth of beneficial microorganisms in the gut. In the study, dietary intervention with fruits and vegetables and/or synbiotic supplementation with be administered to Hong Kong Chinese subjects for eight weeks. Changes in the composition and diversity of intestinal microbiota, and markers indicative of obesity, chronic inflammation and metabolic dysfunction will be assessed throughout the whole period. This study will further provide a scientific basis for the intake of synbiotics for reducing the risk of overweight and obesity among Hong Kong Chinese. Furthermore, the results will bridge to further research into the most desirable gut microbiome profile, hence facilitating personalised nutrition for optimal health.


Description:

This is an 8-week randomized controlled dietary interventional trial.The objectives of this study include: - To investigate the effects of synbiotic supplementation and/or dietary intervention with fruits and vegetables on gut microbial diversity and composition, and on inflammation, metabolic functioning, overweight and obesity among Hong Kong Chinese - To study whether the changes in gut microbial diversity and composition upon the interventions in Hong Kong Chinese are correlated with metabolic functioning and inflammation, as well as overweight or obesity


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date July 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 95 Years
Eligibility Inclusion Criteria: - Waist circumference =90cm in men and =80cm in women - BMI >23.0kg/m2 Exclusion Criteria: - Practicing dietary restrictions - Using cholesterol-lowering, antihypertensive, anti-inflammatory drugs or Chinese medicines - Consuming laxatives, any gastrointestinal medication, probiotics, prebiotics, synbiotics or antibiotics - Smokers - Alcohol abuser - Currently pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Synbiotic supplementation
Daily supplementation of synbiotic
Behavioral:
Dietary intervention
Increased fruits and vegetables consumption

Locations

Country Name City State
Hong Kong The Chinese University of Hong Kong Shatin

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in body weight at week 8 compared with baseline Body weight in kilogram Week 0, 8
Primary Change in Body Mass Index (BMI) at week 8 compared with baseline BMI = Body weight (in kilograms) divided by square of body height (in meters) Week 0, 8
Primary Change in body fat percentage at week 8 compared with baseline Body fat percentage is assessed by bioimpedence Week 0, 8
Secondary Change in fasting glucose at week 8 compared with baseline Fasting glucose in mmol/L Week 0, 8
Secondary Change in fasting insulin at week 8 compared with baseline Fasting insulin in pmol/L Week 0, 8
Secondary Changes in fasting lipids at week 8 compared with baseline Triglycerides in mmol/L
Total cholesterol in mmol/L
HDL-cholesterol in mmol/L
Week 0, 8
Secondary Use of 16S rRNA gene sequencing to assess the changes in the composition of the gut microbiota (bacteriome) of stool samples at week 8 compared with baseline The composition of the gut microbiota (bacteriome) of stool samples is assessed by 16S rRNA gene sequencing Week 0, 8
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2